Zhigang Miao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhigang Miao has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Xingshun Xu
Department of Neurology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
21 shared publications Xiaohua Ma
Department of Neurology the First Affiliated Hospital of Soochow University Suzhou 215000 China
7 shared publicationsJizhen Li
Department of Neurology, Suzhou Kowloon Hospital, Suzhou City, China
6 shared publicationsXiaojing Li
Suzhou science and technology town hospital
6 shared publications- Bo Yang
Department of Anesthesiology, the Second Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, China
5 shared publications Miao Sun
The Institute of Neuroscience, Soochow University, Suzhou City 215006, P.R. China; Institute for Fetology, the First Affiliated Hospital of Soochow University, Suzhou City 215006, P.R. China
5 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (10)
Wdr26 insufficiency causes Skraban-Deardorff syndrome–like neurodevelopmental deficits in mice
Skraban-Deardorff syndrome, a rare neurodevelopmental disorder caused by WD repeat domain 26 ( WDR26 ) haploinsufficiency, is characterized by intellectual disability, seizures, autistic-like behaviors, and craniofacial anomalies. Despite its genetic association with variants disrupting the C-terminal to LisH (CTLH) E3 ubiquitin ligase complex, the molecular mechanisms linking WDR26 dysfunction to neurodevelopmental deficits remain unclear. Here, we demonstrate that Wdr26 heterozygous-KO mice ( Wdr26 +/– ) recapitulated core clinical features of the syndrome, including learning and memory impairments, social dysfunction, heightened seizure susceptibility, and motor deficits, alongside rare craniofacial and dental abnormalities. Mechanistically, Wdr26 haploinsufficiency stabilized RUNX1 translocation partner 1 (RUNX1T1), a transcriptional coactivator critical for neuronal differentiation, by impairing its ubiquitination and proteasomal degradation, consequently disrupting the level of microtubule-associated protein 2 (MAP2), a key regulator of dendritic architecture and synaptic plasticity. Early intervention in neonatal Wdr26 +/– mice (P0.5) using AAV-shRNA–mediated Runx1t1 knockdown reversed MAP2 overexpression and behavioral deficits. Notably, the antipsychotic risperidone ameliorated cognitive and social impairments in Wdr26 +/– mice by upregulating WDR26 levels, suggesting a potential therapeutic avenue. Our findings not only establish the animal model as a robust preclinical tool but also define the WDR26/RUNX1T1/MAP2 regulatory axis as pivotal to the syndrome’s pathogenesis, while identifying actionable therapeutic targets. Skraban-Deardorff syndrome, caused by WDR26 deficiency, impairs protein breakdown, leading to neurodevelopmental issues; reducing Runx1t1 or risperidone treatment alleviates symptoms in mice, highlighting potential therapies.
- 15 May 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (10)
Open AccessWdr26 insufficiency causes Skraban-Deardorff syndrome–like neurodevelopmental deficits in mice
Skraban-Deardorff syndrome, a rare neurodevelopmental disorder caused by WD repeat domain 26 ( WDR26 ) haploinsufficiency, is characterized by intellectual disability, seizures, autistic-like behaviors, and craniofacial anomalies. Despite its genetic association with variants disrupting the C-terminal to LisH (CTLH) E3 ubiquitin ligase complex, the molecular mechanisms linking WDR26 dysfunction to neurodevelopmental deficits remain unclear. Here, we demonstrate that Wdr26 heterozygous-KO mice ( Wdr26 +/– ) recapitulated core clinical features of the syndrome, including learning and memory impairments, social dysfunction, heightened seizure susceptibility, and motor deficits, alongside rare craniofacial and dental abnormalities. Mechanistically, Wdr26 haploinsufficiency stabilized RUNX1 translocation partner 1 (RUNX1T1), a transcriptional coactivator critical for neuronal differentiation, by impairing its ubiquitination and proteasomal degradation, consequently disrupting the level of microtubule-associated protein 2 (MAP2), a key regulator of dendritic architecture and synaptic plasticity. Early intervention in neonatal Wdr26 +/– mice (P0.5) using AAV-shRNA–mediated Runx1t1 knockdown reversed MAP2 overexpression and behavioral deficits. Notably, the antipsychotic risperidone ameliorated cognitive and social impairments in Wdr26 +/– mice by upregulating WDR26 levels, suggesting a potential therapeutic avenue. Our findings not only establish the animal model as a robust preclinical tool but also define the WDR26/RUNX1T1/MAP2 regulatory axis as pivotal to the syndrome’s pathogenesis, while identifying actionable therapeutic targets. Skraban-Deardorff syndrome, caused by WDR26 deficiency, impairs protein breakdown, leading to neurodevelopmental issues; reducing Runx1t1 or risperidone treatment alleviates symptoms in mice, highlighting potential therapies.
- Open Access
- 28 July 2025
- Published by Springer Nature in Clinical Epigenetics
- Vol. 17 (1) , 1-13
Association between outdoor artificial light at night, circadian health, and LDL-C in intracranial artery atherosclerotic stenosis
Outdoor artificial light at night (ALAN) exposure interferes with sleep–wake cycles, leading to sleep disorders, and disrupts metabolic processes, which are closely interconnected. Disruptions in circadian rhythms caused by ALAN may indirectly contribute to metabolic dysregulation, especially in vulnerable populations such as patients with intracranial artery atherosclerotic stenosis (ICAS). This study aimed to evaluate the relationship between outdoor ALAN exposure and low-density lipoprotein cholesterol (LDL-C) control in ICAS patients, and to investigate the underlying mechanisms. We investigated the relationship between outdoor ALAN exposure and LDL-C control in ICAS patients, estimating residential ALAN levels using satellite images. Sleep quality was assessed using validated questionnaires, and generalized additive models were applied to examine the association between ALAN and LDL-C control. Mechanistic insights were explored through animal-based untargeted metabolomics and DNA methylation analyses. A total of 1010 ICAS patients were included, of whom 32 were classified as having poor LDL-C control after three months of management. We found a significant association between outdoor ALAN intensity and poorer LDL-C (control odds ratio = 1.02, 95% CI 1.00, 1.05 per 1 nW/cm−2/sr−1 increase). Sensitivity analyses verified the stability of this association. Metabolic profiling reveals ALAN may regulate lipid metabolism by affecting ATP-binding cassette (ABC) transporter proteins. Additionally, dim ALAN treatment promoted global hypomethylation in mice, while melatonin treatment partially counteracted these effects without reducing the stress response. Increasing ALAN intensity surrounding residences was associated with poorer LDL-C control in ICAS patients, potentially mediated by circadian rhythm disruptions, global methylation levels, and ABC transporter protein expression. These findings suggest that managing urban outdoor lighting could serve as a potential strategy to reduce the public health burden of cerebrovascular and metabolic diseases.
- 28 July 2025
- Published by Springer Nature in Clinical Epigenetics
- Vol. 17 (1) , 1-13
Open AccessAssociation between outdoor artificial light at night, circadian health, and LDL-C in intracranial artery atherosclerotic stenosis
Outdoor artificial light at night (ALAN) exposure interferes with sleep–wake cycles, leading to sleep disorders, and disrupts metabolic processes, which are closely interconnected. Disruptions in circadian rhythms caused by ALAN may indirectly contribute to metabolic dysregulation, especially in vulnerable populations such as patients with intracranial artery atherosclerotic stenosis (ICAS). This study aimed to evaluate the relationship between outdoor ALAN exposure and low-density lipoprotein cholesterol (LDL-C) control in ICAS patients, and to investigate the underlying mechanisms. We investigated the relationship between outdoor ALAN exposure and LDL-C control in ICAS patients, estimating residential ALAN levels using satellite images. Sleep quality was assessed using validated questionnaires, and generalized additive models were applied to examine the association between ALAN and LDL-C control. Mechanistic insights were explored through animal-based untargeted metabolomics and DNA methylation analyses. A total of 1010 ICAS patients were included, of whom 32 were classified as having poor LDL-C control after three months of management. We found a significant association between outdoor ALAN intensity and poorer LDL-C (control odds ratio = 1.02, 95% CI 1.00, 1.05 per 1 nW/cm−2/sr−1 increase). Sensitivity analyses verified the stability of this association. Metabolic profiling reveals ALAN may regulate lipid metabolism by affecting ATP-binding cassette (ABC) transporter proteins. Additionally, dim ALAN treatment promoted global hypomethylation in mice, while melatonin treatment partially counteracted these effects without reducing the stress response. Increasing ALAN intensity surrounding residences was associated with poorer LDL-C control in ICAS patients, potentially mediated by circadian rhythm disruptions, global methylation levels, and ABC transporter protein expression. These findings suggest that managing urban outdoor lighting could serve as a potential strategy to reduce the public health burden of cerebrovascular and metabolic diseases.
- 7 July 2025
- Published by Taylor & Francis in Nanomedicine
- Vol. 20 (15) , 1-16
Research progress on mRNA drug delivery strategies in the nervous system
There has been little progress in the treatment of central nervous system (CNS) disorders in recent decades. To date, new therapeutic agents such as small molecule drugs, cytokines, monoclonal antibodies and vaccines targeting specific antigens are still in the research and development stage and have not yet entered clinical use. With the discovery of gene-editing technology and the development of new therapeutic strategies, mRNA has been developed and used as a new type of drug, showing potential application value in the treatment of various neurological diseases. However, mRNA drugs face difficulties in being delivered to the CNS to exert therapeutic effects. We conducted a review by searching the PubMed database for relevant literature up to now, focusing on the research progress of mRNA drug delivery systems in the nervous system and their applications in neurological diseases, explore the challenges and prospects of mRNA drugs in neurological diseases, and provide reference for the development and implementation of mRNA drugs for neurological diseases.
- 7 July 2025
- Published by Taylor & Francis in Nanomedicine
- Vol. 20 (15) , 1-16
Research progress on mRNA drug delivery strategies in the nervous system
There has been little progress in the treatment of central nervous system (CNS) disorders in recent decades. To date, new therapeutic agents such as small molecule drugs, cytokines, monoclonal antibodies and vaccines targeting specific antigens are still in the research and development stage and have not yet entered clinical use. With the discovery of gene-editing technology and the development of new therapeutic strategies, mRNA has been developed and used as a new type of drug, showing potential application value in the treatment of various neurological diseases. However, mRNA drugs face difficulties in being delivered to the CNS to exert therapeutic effects. We conducted a review by searching the PubMed database for relevant literature up to now, focusing on the research progress of mRNA drug delivery systems in the nervous system and their applications in neurological diseases, explore the challenges and prospects of mRNA drugs in neurological diseases, and provide reference for the development and implementation of mRNA drugs for neurological diseases.
- 29 May 2025
- Published by Elsevier in Neuroscience
- Vol. 579, 85-92
Genetically predicted plasma levels of amino acids and stroke risk: a Mendelian randomization study
- 29 May 2025
- Published by Elsevier in Neuroscience
- Vol. 579, 85-92
Genetically predicted plasma levels of amino acids and stroke risk: a Mendelian randomization study
- Open Access
- 1 January 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 34 (2) , 108220
The prognostic and diagnostic significance of echocardiographic parameters on acute ischemic stroke
- 1 January 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 34 (2) , 108220
Open AccessThe prognostic and diagnostic significance of echocardiographic parameters on acute ischemic stroke
- Open Access
Genetically predicted plasma levels of amino acids and stroke risk: a Mendelian randomization study
Stroke, including ischemic stroke (IS) and small vessel stroke (SVS), is a major cause of morbidity and mortality globally. The role of amino acids in stroke risk and outcomes is not well understood. This study investigates the causal effects of genetically determined amino acid levels on stroke and its functional outcomes using Mendelian randomization (MR). We analyzed data by single nucleotide polymorphisms (SNPs), Inverse-variance weighted (IVW) and so on. After False discovery rate (FDR) correction, we found that Higher genetically determined levels of CSF glycine (odds ratio [OR] per standard deviation [SD] increase, 1.34; 95% confidence interval [CI], 1.14-1.56; P=2.46×10-4), glutamate (odds ratio [OR] per standard deviation [SD] increase, 1.48; 95% confidence interval [CI], 1.17-1.87; P=9.50×10-4), glutamine (odds ratio [OR] per standard deviation [SD] increase, 1.58; 95% confidence interval [CI], 1.29-1.94; P=1.30×10-5), and phenylalanine (odds ratio [OR] per standard deviation [SD] increase, 1.58; 95% confidence interval [CI], 1.32-1.89; P=7.37×10-7) were associated with increased risks of SVS. Higher phenylalanine (odds ratio [OR] per standard deviation [SD] increase, 1.79; 95% confidence interval [CI], 1.26-2.55; P=1.15×10-3) was linked to increased risks of worse IS functional outcomes (modified Rankin Scale score≥3). These findings suggest amino acids as potential biomarkers and therapeutic targets for stroke.
Open AccessGenetically predicted plasma levels of amino acids and stroke risk: a Mendelian randomization study
Stroke, including ischemic stroke (IS) and small vessel stroke (SVS), is a major cause of morbidity and mortality globally. The role of amino acids in stroke risk and outcomes is not well understood. This study investigates the causal effects of genetically determined amino acid levels on stroke and its functional outcomes using Mendelian randomization (MR). We analyzed data by single nucleotide polymorphisms (SNPs), Inverse-variance weighted (IVW) and so on. After False discovery rate (FDR) correction, we found that Higher genetically determined levels of CSF glycine (odds ratio [OR] per standard deviation [SD] increase, 1.34; 95% confidence interval [CI], 1.14-1.56; P=2.46×10-4), glutamate (odds ratio [OR] per standard deviation [SD] increase, 1.48; 95% confidence interval [CI], 1.17-1.87; P=9.50×10-4), glutamine (odds ratio [OR] per standard deviation [SD] increase, 1.58; 95% confidence interval [CI], 1.29-1.94; P=1.30×10-5), and phenylalanine (odds ratio [OR] per standard deviation [SD] increase, 1.58; 95% confidence interval [CI], 1.32-1.89; P=7.37×10-7) were associated with increased risks of SVS. Higher phenylalanine (odds ratio [OR] per standard deviation [SD] increase, 1.79; 95% confidence interval [CI], 1.26-2.55; P=1.15×10-3) was linked to increased risks of worse IS functional outcomes (modified Rankin Scale score≥3). These findings suggest amino acids as potential biomarkers and therapeutic targets for stroke.
- Open Access
- 17 June 2024
- Published by Wiley in Advanced Science
- Vol. 11 (31) , e2400726
Targeting Nr2e3 to Modulate Tet2 Expression: Therapeutic Potential for Depression Treatment
Epigenetic mechanisms such as DNA methylation and hydroxymethylation play a significant role in depression. This research has shown that Ten‐eleven translocation 2 (Tet2) deficiency prompts depression‐like behaviors, but Tet2's transcriptional regulation remains unclear. In the study, bioinformatics is used to identify nuclear receptor subfamily 2 group E member 3 (Nr2e3) as a potential Tet2 regulator. Nr2e3 is found to enhance Tet2's transcriptional activity by binding to its promoter region. Nr2e3 knockdown in mouse hippocampus leads to reduced Tet2 expression, depression‐like behaviors, decreased hydroxymethylation of synaptic genes, and downregulation of synaptic proteins like postsynaptic density 95 KDa (PSD95) and N‐methy‐d‐aspartate receptor 1 (NMDAR1). Fewer dendritic spines are also observed. Nr2e3 thus appears to play an antidepressant role under stress. In search of potential treatments, small molecule compounds to increase Nr2e3 expression are screened. Azacyclonal (AZA) is found to enhance the Nr2e3/Tet2 pathway and exhibited antidepressant effects in stressed mice, increasing PSD95 and NMDAR1 expression and dendritic spine density. This study illuminates Tet2's upstream regulatory mechanism, providing a new target for identifying early depression biomarkers and developing treatments.
- 17 June 2024
- Published by Wiley in Advanced Science
- Vol. 11 (31) , e2400726
Open AccessTargeting Nr2e3 to Modulate Tet2 Expression: Therapeutic Potential for Depression Treatment
Epigenetic mechanisms such as DNA methylation and hydroxymethylation play a significant role in depression. This research has shown that Ten‐eleven translocation 2 (Tet2) deficiency prompts depression‐like behaviors, but Tet2's transcriptional regulation remains unclear. In the study, bioinformatics is used to identify nuclear receptor subfamily 2 group E member 3 (Nr2e3) as a potential Tet2 regulator. Nr2e3 is found to enhance Tet2's transcriptional activity by binding to its promoter region. Nr2e3 knockdown in mouse hippocampus leads to reduced Tet2 expression, depression‐like behaviors, decreased hydroxymethylation of synaptic genes, and downregulation of synaptic proteins like postsynaptic density 95 KDa (PSD95) and N‐methy‐d‐aspartate receptor 1 (NMDAR1). Fewer dendritic spines are also observed. Nr2e3 thus appears to play an antidepressant role under stress. In search of potential treatments, small molecule compounds to increase Nr2e3 expression are screened. Azacyclonal (AZA) is found to enhance the Nr2e3/Tet2 pathway and exhibited antidepressant effects in stressed mice, increasing PSD95 and NMDAR1 expression and dendritic spine density. This study illuminates Tet2's upstream regulatory mechanism, providing a new target for identifying early depression biomarkers and developing treatments.
- 1 June 2024
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 26 (1) , 1-9
p39 Affects Myelin Formation in Cerebral Ischemic Injury
Stroke is a significant public health issue, and research has consistently focused on studying the mechanisms of injury and identifying new targets. As a CDK5 activator, p39 plays a crucial role in various diseases. In this article, we will explore the role and mechanism of p39 in cerebral ischemic injury. We measured the level of p39 using western blot and QPCR at various time points following cerebral ischemia–reperfusion (I/R) injury. The results indicated a significant reduction in the level of p39. TTC staining and behavioral results indicate that the knockout of p39 (p39KO) provides neuroprotection in the short-term. Interestingly, the behavioral dysfunction in p39KO mice was exacerbated after the repair phase of I/R. Further study revealed that this deterioration may be due to demyelination induced by elevated p35 levels. In summary, our study offers profound insights into the significance of p39 in both the acute and repair stages of ischemic injury recovery and a theoretical foundation for future therapeutic drug exploration.
- 1 June 2024
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 26 (1) , 1-9
p39 Affects Myelin Formation in Cerebral Ischemic Injury
Stroke is a significant public health issue, and research has consistently focused on studying the mechanisms of injury and identifying new targets. As a CDK5 activator, p39 plays a crucial role in various diseases. In this article, we will explore the role and mechanism of p39 in cerebral ischemic injury. We measured the level of p39 using western blot and QPCR at various time points following cerebral ischemia–reperfusion (I/R) injury. The results indicated a significant reduction in the level of p39. TTC staining and behavioral results indicate that the knockout of p39 (p39KO) provides neuroprotection in the short-term. Interestingly, the behavioral dysfunction in p39KO mice was exacerbated after the repair phase of I/R. Further study revealed that this deterioration may be due to demyelination induced by elevated p35 levels. In summary, our study offers profound insights into the significance of p39 in both the acute and repair stages of ischemic injury recovery and a theoretical foundation for future therapeutic drug exploration.
- Open Access
- 9 June 2023
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 14, 1198502
5hmC modification regulates R-loop accumulation in response to stress
R-loop, an RNA-DNA hybrid structure, arises as a transcriptional by-product and has been implicated in DNA damage and genomic instability when excessive R-loop is accumulated. Although previous study demonstrated that R-loop is associated with ten-eleven translocation (Tet) proteins, which oxidize 5-methylcytosine to 5-hydroxymethylcytosine (5hmC), the sixth base of DNA. However, the relationship between R-loop and DNA 5hmC modification remains unclear. In this study, we found that chronic restraint stress increased R-loop accumulation and decreased 5hmC modification in the prefrontal cortex (PFC) of the stressed mice. The increase of DNA 5hmC modification by vitamin C was accompanied with the decrease of R-loop levels; on the contrary, the decrease of DNA 5hmC modification by a small compound SC-1 increased the R-loop levels, indicating that 5hmC modification inversely regulates R-loop accumulation. Further, we showed that Tet deficiency-induced reduction of DNA 5hmC promoted R-loop accumulation. In addition, Tet proteins immunoprecipitated with Non-POU domain-containing octamer-binding (NONO) proteins. The deficiency of Tet proteins or NONO increased R-loop levels, but silencing Tet proteins and NONO did not further increase the increase accumulation, suggesting that NONO and Tet proteins formed a complex to inhibit R-loop formation. It was worth noting that NONO protein levels decreased in the PFC of stressed mice with R-loop accumulation. The administration of antidepressant fluoxetine to stressed mice increased NONO protein levels, and effectively decreased R-loop accumulation and DNA damage. In conclusion, we showed that DNA 5hmC modification negatively regulates R-loop accumulation by the NONO-Tet complex under stress. Our findings provide potential therapeutic targets for depression.
- 9 June 2023
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 14, 1198502
Open Access5hmC modification regulates R-loop accumulation in response to stress
R-loop, an RNA-DNA hybrid structure, arises as a transcriptional by-product and has been implicated in DNA damage and genomic instability when excessive R-loop is accumulated. Although previous study demonstrated that R-loop is associated with ten-eleven translocation (Tet) proteins, which oxidize 5-methylcytosine to 5-hydroxymethylcytosine (5hmC), the sixth base of DNA. However, the relationship between R-loop and DNA 5hmC modification remains unclear. In this study, we found that chronic restraint stress increased R-loop accumulation and decreased 5hmC modification in the prefrontal cortex (PFC) of the stressed mice. The increase of DNA 5hmC modification by vitamin C was accompanied with the decrease of R-loop levels; on the contrary, the decrease of DNA 5hmC modification by a small compound SC-1 increased the R-loop levels, indicating that 5hmC modification inversely regulates R-loop accumulation. Further, we showed that Tet deficiency-induced reduction of DNA 5hmC promoted R-loop accumulation. In addition, Tet proteins immunoprecipitated with Non-POU domain-containing octamer-binding (NONO) proteins. The deficiency of Tet proteins or NONO increased R-loop levels, but silencing Tet proteins and NONO did not further increase the increase accumulation, suggesting that NONO and Tet proteins formed a complex to inhibit R-loop formation. It was worth noting that NONO protein levels decreased in the PFC of stressed mice with R-loop accumulation. The administration of antidepressant fluoxetine to stressed mice increased NONO protein levels, and effectively decreased R-loop accumulation and DNA damage. In conclusion, we showed that DNA 5hmC modification negatively regulates R-loop accumulation by the NONO-Tet complex under stress. Our findings provide potential therapeutic targets for depression.
- Top Cited PapersOpen Access
- 3 August 2022
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 14, 975176
Phosphatidylserine, inflammation, and central nervous system diseases
Phosphatidylserine (PS) is an anionic phospholipid in the eukaryotic membrane and is abundant in the brain. Accumulated studies have revealed that PS is involved in the multiple functions of the brain, such as activation of membrane signaling pathways, neuroinflammation, neurotransmission, and synaptic refinement. Those functions of PS are related to central nervous system (CNS) diseases. In this review, we discuss the metabolism of PS, the anti-inflammation function of PS in the brain; the alterations of PS in different CNS diseases, and the possibility of PS to serve as a therapeutic agent for diseases. Clinical studies have showed that PS has no side effects and is well tolerated. Therefore, PS and PS liposome could be a promising supplementation for these neurodegenerative and neurodevelopmental diseases.
- 3 August 2022
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 14, 975176
Top Cited PapersOpen AccessPhosphatidylserine, inflammation, and central nervous system diseases
Phosphatidylserine (PS) is an anionic phospholipid in the eukaryotic membrane and is abundant in the brain. Accumulated studies have revealed that PS is involved in the multiple functions of the brain, such as activation of membrane signaling pathways, neuroinflammation, neurotransmission, and synaptic refinement. Those functions of PS are related to central nervous system (CNS) diseases. In this review, we discuss the metabolism of PS, the anti-inflammation function of PS in the brain; the alterations of PS in different CNS diseases, and the possibility of PS to serve as a therapeutic agent for diseases. Clinical studies have showed that PS has no side effects and is well tolerated. Therefore, PS and PS liposome could be a promising supplementation for these neurodegenerative and neurodevelopmental diseases.